Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine

M.W. Tang, S.Y. Rhee, S. Bertanolio, N. Ford, S. Holmes, K.C. Sigaloff, R.L. Hamers, T.F. de Wit, H.J. Fleury, P.J. Kanki, K. Ruxrungtham, C.A. Hawkins, C.L. Wallis, W. Stevens, G.U. Zyl, W. Manosuthi, M.C. Hosseinipour, N. Ngo-Giang-Huong, L. Belec, M. PeetersA. Aghokeng, T. Bunupuradah, S. Burda, P. Cane, G. Cappelli, C. Charpentier, A.Y. Dagnra, A.K. Deshpande, Z. El-Katib, S.H. Eshleman, J. Fokam, J.C. Gody, D. Katzenstein, D.D. Koyalta, J.J. Kumwenda, M. Lallemant, L. Lynen, V.C. Marconi, N.A. Margot, S. Moussa, T. Ndung'u, P.N. Nyambi, C. Orrell, J.M. Schapiro, R. Schuurman, S. Sirivichayakul, D. Smith, M. Zolfo, M.R. Jordan, R.W. Shafer

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)S70-S77
Number of pages8
JournalJournal of Infectious Diseases
Volume207
Issue numberSuppl 2
Publication statusPublished - 2013

Cite this